reactive arthritis: Reactive arthritis (ReA) is an autoimmune disorder belonging to the group of seronegative spondyloarthropathies and is characterized by the classic triad of arthritis, urethritis and conjunctivitis.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
345 |
4. Check minimum number of eventsNone |
345 |
5. Include endpointsNone |
345 |
6. Filter based on genotype QC (FinnGen only) |
345 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_ARHTROPAT_REACTIVE
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M02
- Name in latin
- Arthropathia post infectionem intestinalem
Similar endpoints
↥List of similar endpoints to
Postdysenteric arthropathy
based on the number of shared cases.
Similar with more cases:
- Reactive arthropathies, FINNGEN
- Reactive arthropathies
- Finngen Rheumatological endpoints
- Arthropathies
- Diseases of the musculoskeletal system and connective tissue
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2221 | 1079 | 1138 |
| Only index persons | 2145 | 1048 | 1097 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 45.19 | 45.69 | 44.72 |
| Only index persons | 44.97 | 45.57 | 44.40 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 345 | 182 | 163 |
| Unadjusted period prevalence (%) | 0.07 | 0.06 | 0.07 |
| Median age at first event (years) | 46.89 | 46.34 | 47.50 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 317
- Matched controls
- 3169
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M02.1
ICD-10 Finland
Postdysenteric arthropathy
+∞
323.0
316
*
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
502.0
108.3
102
*
A07EC01
ATC
sulfasalazine; oral, rectal
20.3
91.9
149
132
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
13.4
70.0
136
168
M13.9
ICD-10 Finland
Arthritis, unspecified
14.7
56.2
100
96
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
12.8
50.2
95
102
H02AB06
ATC
prednisolone; systemic
5.7
44.5
230
1004
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
9.7
43.3
96
136
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.0
41.9
85
102
M02.8
ICD-10 Finland
Other reactive arthropathies
151.9
38.7
40
*
J01MA02
ATC
ciprofloxacin; systemic
3.6
25.3
171
778
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
9.5
20.2
42
50
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
10.4
19.8
39
42
P01BA02
ATC
hydroxychloroquine; oral
5.9
19.4
57
113
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
10.6
19.0
37
39
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
7.9
17.2
40
57
L88
ICPC
Rheumatoid/seropositive arthritis
10.7
17.1
33
34
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.4
15.4
87
321
M45
ICD-10 Finland
Ankylosing spondylitis
10.5
15.0
29
30
H02AB07
ATC
prednisone; oral
3.7
13.0
61
192
A02BC02
ATC
pantoprazole; systemic
2.4
11.9
217
1509
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
11.6
111
557
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
11.8
11.2
20
18
L04AB06
ATC
golimumab; parenteral
22.4
10.8
15
7
L04AB04
ATC
adalimumab; parenteral
8.1
10.1
22
29
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.2
10.1
132
763
M00.9
ICD-10 Finland
Pyogenic arthritis, unspecified
14.0
9.8
16
12
N02AX02
ATC
tramadol; systemic, rectal
2.1
9.3
142
869
S01BA04
ATC
prednisolone; ophthalmic (corticosteroids, plain)
9.5
9.1
18
20
NA6BG
NOMESCO Finland
Sacro-iliac joint MRI examination with high intensity magnet
9.5
9.1
18
20
A02.0
ICD-10 Finland
Salmonella enteritis
20.7
8.5
12
6
M13.1
ICD-10 Finland
Monoarthritis, not elsewhere classified
20.7
8.5
12
6
M02.3
ICD-10 Finland
Reiter disease
+∞
8.4
8
*
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
6.2
7.8
20
34
4AB02
NOMESCO Finland
NA
46.1
7.7
9
*
M25.5
ICD-10 Finland
Pain in joint
2.1
7.6
107
621
M01AE02
ATC
naproxen; oral, rectal
1.9
7.5
189
1370
A04.5
ICD-10 Finland
Campylobacter enteritis
13.8
7.4
12
9
M03.2*A04.6
ICD-10 Finland
Postinfectious arthropathy in enteritis due to Yersinia enterocolitica
+∞
7.3
7
*
TNG10
NOMESCO Finland
Puncture of knee
12.4
7.1
12
10
M46.1
ICD-10 Finland
Sacroiliitis, not elsewhere classified
8.6
6.9
14
17
S01BA01
ATC
dexamethasone; ophthalmic (corticosteroids, plain)
4.2
6.7
24
60
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
5.7
6.7
18
33
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.0
6.7
38
138
M01AH01
ATC
celecoxib; oral (coxibs)
2.3
6.6
65
320
M01AC06
ATC
meloxicam; systemic, rectal
1.9
6.6
118
749
M01AH05
ATC
etoricoxib; oral
1.8
6.3
194
1470
H20.1
ICD-10 Finland
Chronic iridocyclitis
18.5
6.3
9
5
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
6.5
6.2
15
24
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.8
6.1
24
66
L04AB01
ATC
etanercept; parenteral
6.9
6.1
14
21
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.0
6.0
85
489
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
72
65
13.73
70.72
1.6
1.4
—
—
—
0
0
59
59
11.86
53.74
1.8
1.5
16820.4
19593.4
e6/l
0.11
41
44
34
24
15.61
37.87
1.7
1.5
62.2
68.2
%
0.32
25
19
29
17
18.53
35.39
1.7
1.5
29.8
30.0
%
0.01
24
12
254
1614
3.18
20.48
11.0
9.2
3.8
4.1
e9/l
1.81
236
1418
21
23
9.66
17.49
1.4
1.1
7733.0
534621.9
e6/l
0.78
16
18
291
2087
3.52
17.39
7.9
3.8
12.0
10.8
mm/h
0.80
281
1927
33
62
5.78
17.19
1.7
1.5
—
—
—
0
0
108
473
2.87
17.00
1.4
1.2
4.0
9.3
u/ml
0.86
45
195
106
488
2.69
14.92
1.3
1.3
15.1
32.6
iu/ml
2.66
43
167
130
704
2.36
12.61
2.6
2.6
318.8
6881.0
umol/l
2.86
117
623
197
1358
2.05
9.61
5.5
4.6
0.0
0.0
estimate
0.50
53
254
196
1354
2.04
9.45
4.5
3.3
0.0
0.0
estimate
0.00
49
248
50
195
2.83
9.40
2.4
2.3
33.6
20.5
au/ml
—
5
10
198
1378
2.03
9.29
4.6
3.3
0.0
0.0
estimate
0.00
45
236
23
54
4.49
9.27
3.7
3.7
4.1
4.5
e9/l
0.38
23
54
23
54
4.49
9.27
4.1
4.1
55.9
56.9
%
0.16
23
54
265
2133
2.05
7.28
10.3
7.4
76.6
78.5
u/l
0.34
260
2004
158
1108
1.79
6.42
2.4
2.3
75.9
75.8
nmol/l
0.02
150
1002
26
88
3.11
6.26
1.9
1.6
0.3
0.0
iu/ml
—
7
17
321
2855
2.79
5.92
20.5
12.5
25.3
22.5
mg/l
0.65
295
2209
23
79
3.05
5.41
1.3
1.2
—
—
—
0
0
38
171
2.37
5.33
1.6
1.6
—
—
—
0
0
23
80
3.01
5.30
1.3
1.2
—
—
—
0
0
35
158
2.35
4.88
1.7
1.3
—
—
—
0
0
106
715
1.70
4.64
5.6
3.4
0.0
0.0
estimate
0.68
51
244
146
1076
1.62
4.49
4.7
3.4
—
—
—
0
0
304
2708
2.03
4.46
15.7
11.3
88.1
86.2
ml/min/173m2
0.90
284
2204
93
611
1.71
4.46
2.1
1.9
2.9
3.0
mg/l
0.28
81
518
105
724
1.65
4.16
3.1
2.7
0.2
0.5
e6/l
0.94
86
527
86
573
1.67
3.87
1.4
1.5
—
—
—
0
0
85
565
1.67
3.85
1.5
1.5
20.1
20.9
nmol/l
0.24
80
484
96
661
1.63
3.79
1.4
1.3
0.9
1.6
u/ml
0.61
27
194
127
944
1.55
3.59
3.5
2.9
—
—
—
0
0
155
1204
1.52
3.57
2.9
2.7
131.2
119.6
ug/l
0.32
150
1115
64
403
1.72
3.53
1.7
2.2
—
—
—
0
0
11
31
3.63
3.51
1.3
1.2
—
—
—
0
0
60
374
1.73
3.43
1.6
2.0
—
—
—
0
0
246
2119
1.56
3.42
4.1
3.9
14.8
14.7
pmol/l
0.46
237
1935
70
458
1.66
3.35
3.6
2.6
2.4
2.4
mmol/l
0.83
62
403
87
604
1.59
3.28
1.6
1.7
0.7
1.2
mg/l
2.81
67
452
141
1094
1.49
3.17
4.4
4.9
36.3
36.2
g/l
0.07
127
1029
116
867
1.51
3.12
2.9
3.2
2.3
2.4
mmol/l
0.36
106
766
16
63
2.61
3.00
1.1
1.5
—
—
—
0
0
65
433
1.62
2.89
2.7
3.2
0.8
0.8
mmol/l
0.14
60
411
7
13
5.47
2.88
1.1
1.3
5.6
1.7
mmol/l
—
7
13
11
36
3.12
2.83
1.1
1.6
—
—
—
0
0
11
36
3.12
2.83
1.1
1.6
—
—
—
0
0
11
36
3.12
2.83
1.1
1.6
—
—
—
0
0
64
432
1.59
2.69
2.4
2.5
0.5
0.8
e6/l
0.64
37
229
8
20
4.07
2.58
1.1
1.1
282.4
169.2
iu/ml
—
8
20
48
305
1.67
2.56
23.8
17.6
1.1
1.3
inr
0.50
13
41
6
11
5.53
2.55
1.3
1.8
—
—
—
0
0
284
2593
1.54
2.42
4.9
4.5
1.8
2.3
mu/l
0.56
273
2387
6
12
5.07
2.41
1.3
1.8
—
—
—
0
0
18
85
2.18
2.33
2.2
1.4
—
—
—
0
0
14
59
2.43
2.32
1.0
1.2
—
—
—
0
0
10
35
2.91
2.32
1.1
1.6
—
—
—
0
0
12
47
2.61
2.29
1.0
1.1
—
—
—
0
0
41
258
1.67
2.28
2.4
2.4
71.7
36.4
u/l
0.49
35
216
185
1577
1.37
2.23
3.9
5.0
6.5
6.7
mmol/l
0.36
176
1474
10
36
2.83
2.22
1.1
1.6
—
—
—
0
0
10
36
2.83
2.22
1.1
1.6
—
—
—
0
0
6
14
4.34
2.16
1.3
1.8
—
—
—
0
0
59
413
1.52
2.12
2.6
2.6
1.8
2.1
e6/l
0.12
31
210
48
324
1.56
2.03
2.4
2.7
4.5
8.8
umol/l
2.41
43
273
8
26
3.12
2.02
1.5
1.7
—
—
—
0
0
6
16
3.80
1.94
1.5
1.6
—
—
—
0
0
16
78
2.10
1.94
1.1
1.3
—
—
—
0
0
9
34
2.69
1.88
1.4
1.6
—
—
—
0
0
167
1427
1.33
1.87
5.9
6.4
10.2
10.9
umol/l
0.88
161
1354
227
2032
1.34
1.82
3.7
3.2
—
—
—
0
0
120
980
1.34
1.82
3.7
3.3
95.3
38.4
ng/l
0.33
67
626
5
13
3.89
1.72
1.8
1.2
11.2
13.3
u/l
—
5
13
5
13
3.89
1.72
1.0
1.2
—
—
—
0
0
5
13
3.89
1.72
1.0
1.0
—
—
—
0
0
288
2694
1.42
1.62
16.3
13.4
40.6
40.7
%
0.02
228
2091
5
14
3.61
1.62
1.0
1.2
—
—
—
0
0
25
152
1.70
1.61
1.1
1.0
—
—
—
0
0
307
2908
1.51
1.59
16.4
14.2
3.9
4.0
mmol/l
0.97
301
2832
306
2897
1.50
1.59
16.3
14.1
139.4
139.7
mmol/l
0.81
300
2826
26
161
1.67
1.58
1.6
2.0
—
—
—
0
0
12
57
2.15
1.57
1.2
1.1
0.2
1.4
u/ml
—
5
22
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
15
3.37
1.53
1.0
1.1
—
—
—
0
0
15
79
1.94
1.52
1.0
1.1
—
—
—
0
0
18
102
1.81
1.48
1.6
1.7
—
304.0
—
0
5
120
1007
1.29
1.45
2.2
1.8
100.9
97.7
pmol/l
0.33
75
524
62
477
1.37
1.36
1.5
1.7
481.4
18159643.5
pmol/l
0.50
56
402
96
789
1.30
1.35
2.5
2.0
131.5
203.8
u/l
1.81
87
751
30
201
1.54
1.35
1.7
2.1
—
—
—
0
0
37
263
1.46
1.27
2.3
2.2
331.4
384.4
nmol/l
0.98
37
242
16
92
1.78
1.27
1.1
1.2
—
—
—
0
0
145
1264
1.25
1.26
5.4
7.1
1.2
1.2
mmol/l
0.51
122
1087
11
56
2.00
1.23
1.2
1.6
—
—
—
0
0
8
37
2.19
1.22
1.5
1.7
—
—
—
0
0
15
86
1.78
1.21
1.2
1.7
—
—
—
0
0
38
280
1.40
1.10
1.6
1.8
—
—
—
0
0
10
52
1.95
1.07
1.2
1.2
—
—
—
0
0
6
125
0.47
1.06
2.3
4.0
26.2
25.2
mmol/l
—
6
125
9
47
1.94
1.03
1.4
2.0
—
—
—
0
0
7
35
2.02
1.00
1.0
1.2
—
—
—
0
0
50
393
1.32
0.98
2.0
1.9
—
—
—
0
0
7
36
1.96
0.97
1.4
1.8
—
—
—
0
0
0
31
0.00
0.97
0.0
1.2
—
—
—
0
0
28
202
1.42
0.93
1.6
2.8
84.5
70.1
ml/min/173m2
1.65
11
88
15
94
1.62
0.92
1.0
1.4
286.4
313.2
miu/ml
—
6
51
6
28
2.16
0.92
1.2
1.3
—
—
—
0
0
37
283
1.34
0.88
1.7
1.9
—
—
—
0
0
100
868
1.21
0.87
3.3
2.7
57.6
55.8
u/l
0.18
95
800
6
31
1.95
0.85
1.5
1.3
18.9
3.0
ug/l
—
6
26
75
634
1.23
0.84
2.8
2.3
—
—
—
0
0
273
2605
1.23
0.82
5.4
5.5
38.4
39.5
mmol/mol
1.24
262
2449
0
26
0.00
0.78
0.0
1.1
—
—
—
0
0
9
57
1.59
0.71
1.2
1.4
—
—
—
0
0
7
41
1.72
0.70
1.3
1.4
—
—
—
0
0
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
7
41
1.72
0.70
1.3
1.4
—
—
—
0
0
13
85
1.55
0.70
3.1
1.8
—
—
—
0
0
7
119
0.58
0.69
3.7
4.0
46.3
49.8
%
—
7
119
51
423
1.24
0.69
1.7
1.6
1374.4
1182.3
nmol/l
0.67
42
329
7
43
1.64
0.67
1.4
1.7
—
—
—
0
0
31
242
1.31
0.67
3.7
4.2
79.8
25.2
ug/l
0.30
21
201
57
483
1.22
0.64
3.7
3.3
81.1
170.5
ng/l
0.75
39
342
61
521
1.21
0.63
2.9
2.7
0.6
0.7
ug/l
0.83
36
319
8
50
1.61
0.61
1.5
1.7
—
—
—
0
0
32
256
1.28
0.59
4.6
2.9
—
—
—
0
0
22
282
0.77
0.54
5.5
10.6
-0.0
1.0
mmol/l
0.92
16
229
10
144
0.69
0.50
1.4
1.4
—
—
—
0
0
10
67
1.51
0.50
1.6
1.8
—
—
—
0
0
7
45
1.57
0.49
1.4
1.3
—
—
—
0
0
137
1274
1.12
0.47
3.9
4.0
—
—
—
0
0
10
68
1.48
0.47
4.3
3.0
—
3.6
—
0
6
5
31
1.62
0.43
1.0
1.1
—
—
—
0
0
5
31
1.62
0.43
1.6
1.2
44.6
53.9
u/l
—
5
21
5
32
1.57
0.42
1.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
1.0
—
0
10
11
149
0.73
0.41
4.0
2.4
39.5
56.2
u/ml
0.32
11
141
12
88
1.38
0.40
3.3
2.1
—
—
—
0
0
13
98
1.34
0.38
3.2
1.4
1.3
1.2
g/l
1.22
13
93
9
68
1.33
0.38
1.6
1.8
—
—
—
0
0
8
114
0.69
0.37
1.3
1.4
271.5
295.5
mu/l
—
8
104
70
634
1.13
0.37
3.1
3.1
1784.9
998.6
ng/l
0.43
60
518
6
44
1.37
0.34
2.5
4.4
—
3856.0
—
0
7
7
54
1.30
0.30
1.6
1.4
—
—
—
0
0
12
93
1.30
0.30
3.6
1.9
0.5
4.1
ug/l
0.66
12
85
29
334
0.86
0.30
4.2
4.3
31.4
31.4
%
0.00
21
228
296
2909
1.12
0.28
4.7
4.7
2.9
2.8
mmol/l
0.17
283
2714
82
763
1.10
0.28
1.8
1.7
1.3
1.5
mmol/l
0.97
72
653
5
72
0.69
0.26
1.6
1.5
—
—
—
0
0
5
72
0.69
0.26
1.6
1.5
—
—
—
0
0
35
311
1.14
0.26
6.4
7.3
105.3
103.8
mmol/l
1.42
35
302
76
709
1.09
0.25
3.5
3.8
21.3
22.0
%
0.17
34
306
9
76
1.19
0.25
1.4
2.8
—
—
—
0
0
209
2030
1.07
0.24
3.4
3.3
50.0
48.5
u/l
0.11
198
1916
16
133
1.21
0.24
1.6
1.6
—
—
—
0
0
20
233
0.85
0.24
2.3
3.9
1.3
1.9
mmol/l
0.25
14
188
13
106
1.24
0.23
1.4
2.3
—
—
—
0
0
292
2876
1.10
0.23
4.4
4.3
4.8
4.7
mmol/l
0.27
280
2700
5
41
1.22
0.22
1.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
10
123
0.81
0.20
1.4
1.7
—
—
—
0
0
6
48
1.25
0.20
1.3
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
12
99
1.22
0.20
1.2
1.4
—
—
—
0
0
23
204
1.14
0.18
1.3
1.2
98.5
126.9
iu/ml
—
10
79
19
166
1.15
0.18
2.4
3.4
5.2
5.2
kpa
0.01
14
158
93
887
1.07
0.18
4.3
4.3
1.6
2.0
ug/l
1.13
84
797
7
58
1.21
0.18
1.0
1.4
—
103.1
—
0
11
290
2865
1.08
0.16
4.2
4.2
1.5
1.4
mmol/l
0.45
279
2672
8
70
1.15
0.16
1.0
1.2
—
—
—
0
0
274
2773
0.94
0.14
3.9
3.8
1.3
1.3
mmol/l
0.08
262
2573
44
469
0.93
0.14
1.3
1.4
—
—
—
0
0
5
64
0.78
0.08
1.0
1.2
—
—
—
0
0
7
65
1.08
0.08
1.0
1.2
—
53.3
—
0
5
7
67
1.05
0.08
1.4
1.4
—
—
—
0
0
6
72
0.83
0.07
1.2
1.3
—
—
—
0
0
29
304
0.95
0.06
1.4
1.8
—
—
—
0
0
277
2756
1.03
0.04
4.5
4.3
5.8
5.9
mmol/l
0.46
267
2549
32
312
1.03
0.02
7.5
6.9
—
—
—
0
0
14
139
1.01
0.00
1.6
1.5
—
—
—
0
0
5
49
1.02
0.00
1.6
3.0
16.0
33.5
u/ml
—
5
49
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
7
78
0.90
0.00
1.6
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
7
78
0.90
0.00
1.3
2.1
230.1
180.9
%
—
7
78
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
5
54
0.92
0.00
1.4
1.8
—
—
—
0
0
8
85
0.94
0.00
1.8
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
68.6
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
64
0.94
0.00
2.2
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint ARTRHO_POSTDYSENTERIC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ARTRHO_POSTDYSENTERIC | 1.182 [0.9, 1.55] | 0.228 |
| Birth year | 0.999 [0.99, 1.01] | 0.765 |
During the follow-up period (1.1.1998 — 31.12.2019), 79 out of 974 females with ARTRHO_POSTDYSENTERIC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ARTRHO_POSTDYSENTERIC | 0.814 [0.65, 1.02] | 0.071 |
| Birth year | 0.986 [0.98, 1.0] | 0.007 |
During the follow-up period (1.1.1998 — 31.12.2019), 80 out of 1010 males with ARTRHO_POSTDYSENTERIC died.
Mortality risk
Mortality risk for people of age
years, who have ARTRHO_POSTDYSENTERIC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.104% | 0.138% |
| 5 | 0.787% | 0.85% |
| 10 | 1.998% | 2.199% |
| 15 | 3.78% | 4.239% |
| 20 | 6.482% | 7.309% |
Relationships between endpoints
↥Index endpoint: ARTRHO_POSTDYSENTERIC – Postdysenteric arthropathy
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data